Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education
Publication: Cannabis and Cannabinoid Research
Volume 4, Issue Number 3
Abstract
Introduction: Rates of cannabis consumption range from 40% to 74% among people living with HIV (PLWH). Little is known about the reasons for cannabis use, related modes of administration, effectiveness for symptom relief, or undesirable effects in the modern antiretroviral therapy (ART) era. Our aim was to conduct an exploratory study to identify potential areas for further evaluation and intervention.
Materials and Methods: From January to June 2018, health care providers at the Chronic Viral Illness Service in Montreal, Canada, asked their patients about cannabis use during routine visits. Patients reporting cannabis use were invited to complete a 20-min coordinator-administered questionnaire. Questions related to patterns of use, modes of administration, reasons for use, secondary effects, and HIV health-related factors (e.g., adherence to ART).
Results: One hundred and four PLWH reporting cannabis use participated. Median age was 54 years (interquartile range [IQR] 46–59), 13% were female, and 42% were HIV-Hepatitis C co-infected. Median CD4 count was 590 cells/mm3 (IQR 390–821), 95% of participants were on ART, and 88% had suppressed viral loads. Reported cannabis use was more than once daily (32%); daily (25%); weekly (22%); monthly (17%); and rarely (twice to thrice per year; 6%). The majority of participants (97%) smoked dry plant cannabis. Other modes included vaping (12%), capsules (2%), edibles (21%), and oils (12%). Common reasons for cannabis use were for pleasure (68%) and to reduce anxiety (57%), stress (55%), and pain (57%). Many participants found cannabis “quite effective” or “extremely effective” (45%) for symptom relief. Secondary effects included feeling high (74%), increased cough (45%), paranoia (22%), palpitations (20%), and increased anxiety (21%). Over two-thirds of participants indicated that secondary effects were not bothersome at all. Most participants (68%) rarely missed doses of their ART, while 27% missed occasionally (once to twice per month). The most commonly accessed sources of information about cannabis were friends (77%) and the internet (55%).
Conclusion: The most common reasons for cannabis use in our population were for pleasure, followed by reduction of stress/anxiety and symptoms associated with a medical condition. Most smoke cannabis and rate cannabis as quite effective for symptom relief. While many participants experience secondary effects, most are not bothered by these symptoms. Amid widespread changes in the regulatory landscape of recreational cannabis, health care providers should be prepared to answer questions about cannabis.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Ware MA, Rueda S, Singer K, et al. Cannabis use by persons living with HIV/AIDS: patterns and prevalence of use. J Cannabis Ther. 2003;3:3–15.
2. Aggarwal SK, Carter GT, Sullivan MD, et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5:153–168.
3. Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002;16:543–550.
4. Patel SM, Thames AD, Arbid N, et al. The aggregate effects of multiple comorbid risk factors on cognition among HIV-infected individuals. J Clin Exp Neuropsychol. 2013;35:421–434.
5. Lorkiewicz SA, Ventura AS, Heeren TC, et al. Lifetime marijuana and alcohol use, and cognitive dysfunction in people with human immunodeficiency virus infection. Subst Abus. 2018;39:116–123.
6. Furler MD, Einarson TR, Millson M, et al. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS. 2004;18:215–228.
7. Costiniuk CT, Brunet L, Rollet-Kurhajec KC, et al. Tobacco smoking is not associated with accelerated liver disease in human immunodeficiency virus-hepatitis C coinfection: a longitudinal cohort analysis. Open Forum Infect Dis. 2016;3:ofw050.
8. Okafor CN, Cook RL, Chen X, et al. Prevalence and correlates of marijuana use among HIV-seropositive and seronegative men in the Multicenter AIDS Cohort Study (MACS), 1984–2013. Am J Drug Alcohol Abuse. 2017;43:556–566.
9. Ware MA, Doyle CR, Woods R, et al. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003;102:211–216.
10. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54–61.
11. Tashkin DP, Shapiro BJ, Lee YE, et al. Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis. 1975;112:377–386.
12. Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis. 1974;109:420–428.
13. Abdallah SJ, Smith BM, Ware MA, et al. Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial. Ann Am Thorac Soc. 2018;15:1146–1158.
14. Bonn-Miller MO, Oser ML, Bucossi MM, et al. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014;37:1–10.
15. Wood E, Hogg RS, Yip B, et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:261–268.
16. Slawson G, Milloy MJ, Balneaves L, et al. High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2015;19:120–127.
17. Sparacino CM, Hyldburg PA, Hughes TJ. Chemical and biological analysis of marijuana smoke condensate. NIDA Res Monogr. 1990;99:121–140.
18. Morris MA, Jacobson SR, Kinney GL, et al. Marijuana Use associations with pulmonary symptoms and function in tobacco smokers enrolled in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS). Chronic Obstr Pulm Dis. 2018;5:46–56.
19. Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis. Ann Intern Med. 2018;169:106–115.
20. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J. 2007;4:11.
21. Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167:221–228.
22. Hancox RJ, Poulton R, Ely M, et al. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 2010;35:42–47.
23. Tashkin DP, Coulson AH, Clark VA, et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis. 1987;135:209–216.
24. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307:173–181.
25. Kempker JA, Honig EG, Martin GS. The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. Ann Am Thorac Soc. 2015;12:135–141.
26. Wilkinson ST, Radhakrishnan R, D'Souza DC. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep. 2014;1:115–128.
27. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010;110:137–143.
28. Fischer B, Russell C, Sabioni P, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107:e1–e12.
29. Helleberg M, Gerstoft J, Afzal S, et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014;28:1499–1508.
30. Cook JA, Burke-Miller JK, Steigman PJ, et al. Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS Behav. 2018;22:3141–3154.
31. Ezzati M, Lopez AD. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control. 2004;13:388–395.
32. Statistics_Canada. Health Trends 2014. Statistics Canada Catalogue No. 82-213-XWE. http://www12.statcan.gc.ca/health-sante/82-213/index.cfm?Lang=ENG (last accessed July 7, 2018).
33. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–728.
34. Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11:75–82.
35. Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One. 2014;9:e92842.
36. Merlin JS, Westfall AO, Raper JL, et al. Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr. 2012;61:164–170.
37. Miaskowski C, Penko JM, Guzman D, et al. Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection. J Pain. 2011;12:1004–1016.
38. Newshan G, Bennett J, Holman S. Pain and other symptoms in ambulatory HIV patients in the age of highly active antiretroviral therapy. J Assoc Nurses AIDS Care. 2002;13:78–83.
39. Bruce RD, Merlin J, Lum PJ, et al. 2017 HIVMA of IDSA clinical practice guideline for the management of chronic pain in patients living with HIV. Clin Infect Dis. 2017;65:e1–e37.
40. Aouizerat BE, Miaskowski CA, Gay C, et al. Risk factors and symptoms associated with pain in HIV-infected adults. J Assoc Nurses AIDS Care. 2010;21:125–133.
41. Belle-Isle L, Hathaway A. Barriers to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care. 2007;19:500–506.
42. Ilgen MA, Perron B, Czyz EK, et al. The timing of onset of pain and substance use disorders. Am J Addict. 2010;19:409–415.
43. Sohler NL, Starrels JL, Khalid L, et al. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. Subst Use Misuse. 2018;53:1602–1607.
44. Socias ME, Kerr T, Wood E, et al. Intentional cannabis use to reduce crack cocaine use in a Canadian setting: a longitudinal analysis. Addict Behav. 2017;72:138–143.
45. Fischer B, Pang M, Tyndall M. The opioid death crisis in Canada: crucial lessons for public health. Lancet Public Health. 2019;4:e81–e82.
46. Skalski LM, Towe SL, Sikkema KJ, et al. The impact of marijuana use on memory in HIV-infected patients: a comprehensive review of the HIV and marijuana literatures. Curr Drug Abuse Rev. 2016;9:126–141.
47. Crane NA, Schuster RM, Fusar-Poli P, et al. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23:117–137.
48. Harris GE, Dupuis L, Mugford GJ, et al. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. Spring 2014;25:e1–e7.
49. Palmer AK, Klein MB, Raboud J, et al. Cohort profile: the Canadian observational cohort collaboration. Int J Epidemiol. 2011;40:25–32.
50. Cescon A, Patterson S, Chan K, et al. Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. PLoS One. 2013;8:e83649.
Cite this article as: Costiniuk CT, Saneei Z, Salahuddin S, Cox J, Routy J-P, Rueda S, Abdallah SJ, Jensen D, Lebouché B, Brouillette M-J, Klein M, Szabo J, Frenette C, Giannakis A, Jenabian M-A (2019) Cannabis consumption in people living with HIV: reasons for use, secondary effects, and opportunities for health education, Cannabis and Cannabinoid Research 4:3, 204–213, DOI: 10.1089/can.2018.0068.
Information & Authors
Information
Published In
Cannabis and Cannabinoid Research
Volume 4 • Issue Number 3 • September 2019
Pages: 204 - 213
Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers.
History
Published online: 23 September 2019
Published in print: September 2019
Published ahead of print: 14 May 2019
Topics
Authors
Author Disclosure Statement
The authors have received free product from Tilray, Inc. for use in a clinical trial (Canadian HIV Trials Network PT028), but no financial support was received for this or other studies.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.